Tenpoint Therapeutics has announced a major financing and regulatory milestone that accelerates its entry into the commercial ophthalmology market. The company secured $235 million in combined equity and debt financing as it prepares to launch YUVEZZI, its lead treatment for presbyopia. The announcement follows U.S. regulatory approval, marking a decisive shift from development to commercialization.
Capital Raise Supports Market Entry
Tenpoint raised $85 million through a Series B preferred stock financing led by Janus Henderson, EQT Nexus, Hillhouse, and the British Business Bank. Existing investors including EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, and Wille also participated in the round. Their continued backing signals confidence in Tenpoint’s execution and long-term market opportunity.
Alongside the equity raise, the company secured a $150 million non-dilutive senior secured term loan facility from Hercules Capital. The debt financing strengthens Tenpoint’s balance sheet while limiting dilution ahead of its commercial launch. This combined structure provides the company with flexibility to fund manufacturing, marketing, and distribution activities.
Regulatory Approval Enables Commercial Launch
The financing coincides with approval of YUVEZZI by the U.S. Food and Drug Administration for the treatment of presbyopia. YUVEZZI is approved as the only dual-agent, once-daily eye drop available for this condition in the United States. The approval allows Tenpoint to proceed with a planned launch in early Q2 2026.
Presbyopia is an age-related condition that reduces near vision and affects a large and growing population. Despite its prevalence, pharmaceutical treatment options have remained limited. The regulatory decision positions Tenpoint to address a significant unmet need with a differentiated therapy.
Product Differentiation and Clinical Positioning
YUVEZZI combines carbachol and brimonidine tartrate into a single ophthalmic solution intended for daily use. The dual-agent formulation is designed to improve near vision while maintaining a favorable safety and tolerability profile. Tenpoint believes this balance differentiates YUVEZZI from existing presbyopia treatments.
The company is positioning YUVEZZI as a long-term vision correction option rather than a situational or short-term solution. This approach aligns with how patients manage other chronic age-related conditions. As a result, Tenpoint expects adoption among both patients and eye care professionals.
Market Size and Commercial Opportunity
Presbyopia affects nearly 128 million people in the United States and approximately two billion people worldwide. The condition represents one of the largest addressable markets in ophthalmology. Tenpoint views the market as structurally underpenetrated by pharmaceutical solutions.
Initial commercialization efforts will focus on the U.S. market before expanding internationally. The company plans to emphasize physician engagement and patient education during the rollout. This strategy is intended to support sustained adoption beyond the initial launch period.
Leadership and Investor Perspective
Tenpoint’s leadership emphasized the strategic importance of aligning regulatory approval with financing. Chief Executive Officer Henric Bjarke stated that the strengthened balance sheet enables focused execution of the company’s launch strategy. He highlighted investor support as validation of both the product and the management team.
Investors cited the company’s clinical progress and operational readiness as key factors behind the Series B financing. Janus Henderson pointed to YUVEZZI’s safety profile and commercial potential as central to its investment decision. The firm also noted Tenpoint’s positioning ahead of launch.
With FDA approval secured and $235 million in new financing, Tenpoint Therapeutics enters a defining phase of growth. The company is now positioned to execute a full-scale commercial launch with sufficient capital and strategic clarity. As YUVEZZI reaches the market, Tenpoint is establishing itself as a notable new player in global ophthalmology.